期刊文献+

肺腺癌组织中lncRNA CADM1-AS1表达及其临床意义 被引量:6

Expression and clinical significance of lncRNA CADM1-AS1 in lung adenocarcinoma
下载PDF
导出
摘要 目的探讨长链非编码lncRNA CADM1-AS1在肺腺癌组织中的表达水平及其临床意义。方法收集于本院行手术切除的72例肺腺癌组织及对应癌旁组织,采用实时定量PCR(q PCR)法检测以上组织标本中的CADM1-AS1水平,分析CADM1-AS1水平与临床病理参数(性别、年龄、肿瘤大小、分化类型、临床分期、T分期、吸烟史和淋巴结转移)的关系,同时根据远期生存资料比较不同CADM1-AS1表达水平的中位总生存期(OS)。进一步采用q PCR法检测常见非小细胞肺癌株A549、SPC-A、NCI-H1650和NCI-H1299中的CADM1-AS1水平。采用受试者工作特征曲线(ROC)评价组织CADM1-AS1水平在肺腺癌早期诊断中的效能。结果肺腺癌组织中的CADM1-AS1水平低于癌旁组织,且与正常支气管上皮细胞株16HBE相比,非小细胞肺癌株的CADM1-AS1均为低表达,差异有统计学意义(P均<0.05),且按照由高至低依次为NCI-H1299>SPCA>NCI-H1650>A549;CADM1-AS1表达与肺腺癌的TNM分期、分化类型、肿瘤大小、T分期及淋巴结转移有关,其中TNMⅡ、Ⅲ期、低未分化、肿瘤最大径>3 cm、T分期T3、T4期及有淋巴结转移组织的CADM1-AS1水平均低于对应项(P均<0.05);CADM1-AS1高水平者的中位OS为32.5个月,高于低水平者的16.0个月,差异有统计学意义(P均<0.05)。组织CADM1-AS1水平在肺腺癌早期诊断中的价值较好,其曲线下面积为0.874,灵敏度和特异度分别为87.8%和85.2%。结论 CADM1-AS1在肺腺癌组织及非小细胞肺癌细胞株中低表达,且与TNM分期、分化类型等临床病理参数及预后有关,可能在肺腺癌的发生发展中有一定作用,同时对于肺腺癌的早期诊断有较好价值。 Objective To explore the expression and clinical significance of lncRNA CADM1-AS1 in lung adenocarcinoma.Methods In this study,72 cases of lung adenocarcinoma tissues and corresponding para carcinoma tissues were collected from our hospital. Real time quantitative PCR( q PCR) was used to detect the level of CADM1-AS1 in tissue samples. The relationship between CADM1-AS1 level and clinical pathological parameters( gender,age,tumor size,differentiation,clinical stage,T stage,smoking history and lymph node metastasis) was analyzed. The median overall survival( OS) was compared between different CADM1-AS1 levels according to the long-term survival data. The levels of CADM1-AS1 in common non-small cell lung cancer cells( NCI-H1299,SPC-A,NCI-H1650 and A549) were detected by q PCR assay. The effectiveness of CADM1-AS1 level in early diagnosis of lung cancer was evaluated by the receiver operating characteristic curve( ROC). Results The level of CADM1-AS1 in lung adenocarcinoma tissues was lower than that in para carcinoma tissues( P〈0. 05). Compared with the normal bronchial epithelial cell line 16 HBE,the CADM1-AS1 of the non small cell lung cancer was lower( P〈0. 05). CADM1-AS1 level was related to TNM stage,differentiation,tumor size,T stage and lymph node metastasis of lung adenocarcinoma( P〈0. 05). The median OS in patients with high CADM1-AS1 level was32. 5 months,higher than 16. 0 months of patients with low CADM1-AS1 level( P〈0. 05). The value of CADM1-AS1 in the early diagnosis of lung adenocarcinoma was good with the area under the curve of 0. 874,and the sensitivity and specificity were 87. 8% and85. 2% respectively. Conclusion There were relative low levels of CADM1-AS1 in lung adenocarcinoma cell line and non-small cell lung cancer cell line. The CADM1-AS1 level is related to the TNM stage,differentiation and prognosis,which may be related to the occurrence and development of lung adenocarcinoma. It has a good value for early diagnosis of lung adenocarcinoma.
出处 《临床肿瘤学杂志》 CAS 2015年第11期1018-1022,共5页 Chinese Clinical Oncology
关键词 肺腺癌 长链非编码RNA CADM1-AS1 临床意义 Lung adenocarcinoma Long non-encoding RNA CADM1-AS1 Clinical significance
  • 相关文献

参考文献14

  • 1Siegel R, Naishadham D, Jemal A. Cancer statistics [ J]. CA- Cancer J Clin, 2013, 63(1):11-30.
  • 2强光亮,刘德若,中岛淳,安乐真树,似鸟纯一,牛久绫.CCR4在T_1期肺腺癌组织中的表达及其临床意义[J].临床肿瘤学杂志,2014,19(12):1081-1085. 被引量:2
  • 3Liu H, Lv Z, Guo E. Knockdown of long noncoding RNA SPRY4-IT1 suppresses glioma cell proliferation, metastasis and epithelial-mesenchymal transition [ J ]. Int J Clin Exp Pathol, 2015, 8(8) :9140-9146.
  • 4Chen S, Shao C, Xu M, et al. Macrophage infiltration promotes invasiveness of breast cancer cells via activating long non-codin- gRNA UCA1 [J]. Int J Clin Exp Pathol, 2015, 8(8) :9052 -9061.
  • 5Xiao H, Yuan Z, Guo D, et al. Genome-wide identification of long noncoding RNA genes and their potential association with fe- cundity and virulence in rice brown planthopper, Nilaparvata lu- gens[J]. BMC Genomics, 2015, 16(1) :749.
  • 6郑清盛,王守铭,吴大庆,付军,刘新,王梽,刘建郭.长链非编码RNA在肝细胞肝癌组织中的表达及临床意义[J].中华实验外科杂志,2014,31(4):840-842. 被引量:9
  • 7Dang Y, Lan F, Ouyang X, et al. Expression and clinical signifi- cance of long non-coding RNA HNF1A-AS1 in human gastric cancer[J]. World J Surg Oncol, 2015, 13:302.
  • 8Yao J, Chen Y, Wang Y, et al. Decreased expression of a novel lncRNA CADM1-AS1 is associated with poor prognosis in patients with clear cell renal cell carcinomas [ J ]. Int J Clin Exp Pathol, 2014, 7(6) :2758-2767.
  • 9Spizzo R, Almeida MI, Colombatti A, et al. Long non-coding RNAs and cancer: A new frontier of translational research? [ J ]. Oncogenc, 2012, 31 ( 43 ) : 4577- 4787.
  • 10Huarte M, Rinn JL. Large non-coding RNAs: Missing links in cancer? [J]. Hum Mol Genet, 2010, 19(2) : 152-161.

二级参考文献20

  • 1Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs:insights into functions [ J 1. Nat Rev Genet,2009,10 ( 3 ) : 155-159.
  • 2Wilusz JE, Sunwoo H, Spector DL. Long noncoding RNAs: functional surprises from the RNA world[ J]. Genes Dev,2009,23 (13) :1494- 1504.
  • 3Lee H J, Kim K J, Park MH,et al. Single-nucleotide polymorphisms and haplotype LD analysis of the 29-kb IGF2 region on chromosome 11 plS. 5 in the Korean population. Hum Hered,2005,60(2 ) :73-80.
  • 4Vu TH, Hoffman AR. Promoter-specific imprinting of the human insu- lin-like growth factor-II gene. Nature,1994,371 (6499) :714-717.
  • 5Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma[J]. Nature, 2014, 511(7511) :543-550.
  • 6A1-Banna NA, Vaci M, Slauenwhite D, et al. CCR4 and CXCR3 play different roles in the migration of T cells to inflammation in skin, arthritic joints, and lymph nodes[J]. Eur J Immunol, 2014, 44(6) : 1633-1643.
  • 7Yu QM, Yu CD, Ling ZQ. Elevated circulating CD19+lympho- cytes predict survival advantage in patients with gastric cancer [J]. Asian Pac J Cancer Prev,2012,13(5) :2219-2224.
  • 8Pease JE, Horuk R. Recent progress in the development of antag- onists to the chemokine receptors CCR3 and CCR4 [ J ]. Expert Opin Drug Discov, 2014, 9 ( 5 ) : 467-483.
  • 9Li JY, Ou ZL, Yu SJ, et al. The chemokine receptor CCR4 pro- motes tumor growth and lung metastasis in breast cancer [ J ]. Breast Cancer Res Treat, 2012, 131 ( 3 ) : 837- 848.
  • 10Menetrier-Caux C, Curiel T, Faget J, et al. Targeting regulatory T cells[J]. Target Oncol, 2012, 7( 1 ) : 15-28.

共引文献9

同被引文献24

引证文献6

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部